lenacapavir LEN (CAI)

Medication with unique mechanism of action, DHHS recommended for heavily treatment-experienced people
Long-acting Capsid Inhibitor

Standard Dose

Sunlenca is administered as two 463.5 mg (1.5 mL) subcutaneous injections (for a total dose of 927 mg) in the abdomen once every six months by a healthcare provider. It must be used as part of a regimen with another antiretroviral(s), the majority of which are taken daily.

There are two initiation dosing schedules, both consisting of a combination of lenacapavir tablets and subcutaneous injections. The first consists of the two subcutaneous injections + 600 mg oral LEN (two 300 mg tablets) on Day 1 and 600 mg oral LEN on Day 2. The second consists of 600 mg oral LEN on Day 1 and Day 2, 300 mg on Day 8 and the two injections on Day 15. The first maintenance dose begins six months later, give or take two weeks. If more than 28 weeks passes without the maintenance dose, re-start therapy with an initiation dosing followed by the maintenance dose six months later.
  • See package insert for more complete information on potential side effects and interactions.


Gilead Sciences, Inc.;
(800) GILEAD-5 (445-3235)


Two 1.5 ml injections (SQ): $23,400.00/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments